Clinical Observation of Jinlida Granule Combined with Tongxinluo Capsule on Diabetic Retinopathy

WEI Geng; XING Yu-wei; CAO Liu; ZHANG Su-ming; HE Su-yan

doi:10.13422/j.cnki.syfjx.20181723

您当前的位置：

首页 >

文章列表页 >

Clinical Observation of Jinlida Granule Combined with Tongxinluo Capsule on Diabetic Retinopathy

更新时间：2024-01-04

- Clinical Observation of Jinlida Granule Combined with Tongxinluo Capsule on Diabetic Retinopathy
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 18, Pages: 170-174(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20181723
  CLC： R259;R276.7
- Published：2018
- 稿件说明：
移动端阅览
WEI Geng, XING Yu-wei, CAO Liu, et al. Clinical Observation of Jinlida Granule Combined with Tongxinluo Capsule on Diabetic Retinopathy[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(18): 170-174.
DOI：

WEI Geng, XING Yu-wei, CAO Liu, et al. Clinical Observation of Jinlida Granule Combined with Tongxinluo Capsule on Diabetic Retinopathy[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(18): 170-174. DOI： 10.13422/j.cnki.syfjx.20181723.

摘要

目的：观察津力达颗粒联合通心络胶囊对2型糖尿病非增殖期视网膜病变患者临床疗效、中医证候、糖脂代谢、胰岛素抵抗指数及血清白细胞介素-6（IL-6）的影响。方法：将62例2型糖尿病非增殖期视网膜病变患者随机分为两组，均给予基础治疗。对照组32例给予羟苯磺酸钙胶囊治疗，治疗组30例在对照组的基础上加用津力达颗粒联合通心络胶囊治疗。两组患者连续用药12周后统计临床疗效及中医证候改善情况，并观察空腹血糖（FPG），餐后2 h血糖（2 hPG），糖化血红蛋白（HbA1c），三酰甘油（TG），总胆固醇（TC），高密度脂蛋白（HDL-C），低密度脂蛋白（LDL-C），胰岛素抵抗指数，IL-6的变化情况。结果：治疗组临床疗效及中医证候改善情况明显高于对照组（P<0.05）；两组患者治疗后FPG，2 hPG，HbA1c，TG，TC，LDL-C水平，胰岛素抵抗指数，IL-6水平均较本组治疗前明显降低，HDL-C水平较本组治疗前明显升高，且治疗组优于对照组（P<0.05）。结论：津力达颗粒联合通心络胶囊治疗2型糖尿病非增殖期视网膜病变疗效明显，其作用可能与调节糖脂代谢、改善胰岛素抵抗和降低血清炎症因子有关。

Abstract

Objective: To observe the clinical efficacy and effect of Jinlida granule combined with Tongxinluo capsule on traditional Chinese medicine (TCM) syndromes

glucose metabolism

lipid metabolism and levels of interleukin-6(IL-6) in serum of patients with non-proliferative retinopathy of type 2 diabetes. Method: The 62 patients with non-proliferative retinopathy of type 2 diabetes were randomly divided into two groups

and all of them were given with basic treatment. The control group (32 patients) were treated with calcium hydroxybenzene sulfonate capsule

and the treatment group (30 patients) were treated with Jinlida granule combined with Tongxinluo capsule on the basis of control group. After 12 weeks

clinical efficacy

TCM syndromes improvement

fasting plasma glucose (FPG)

2 h postprandial blood glucose (2 hPG)

glycosylated hemoglobin (HbA1c)

triacylglycerol (TG)

total cholesterol (TC)

high-density lipoprotein-C (HDL-C)

low-density lipoprotein-C (LDL-C)

insulin resistance index (HOMA-IR) and IL-6 in two groups were observed and compared. Result: The clinical efficacy and the improvement of TCM syndromes in treatment group were significantly better than those in control group (P<0.05). The FPG

2 hPG

HbA1c

HDL-C

insulin resistance index and IL-6 were significantly decreased

and the HDL-C was significantly increased in both groups after treatment

and the treatment group were better than control group (P<0.05). Conclusion: Jinlida granule combined with Tongxinluo capsule has a significant therapeutic effect on non-proliferative retinopathy of type 2 diabetes

and the mechanism may be related to regulating glucose and lipid metabolism

improving insulin resistance and reducing serum inflammatory factors.

关键词

Keywords

references

Views

142

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Protective Effect of Total Lignans of Arctii Fructus on Retina in Rat Model of Type 2 Diabetes Mellitus

Investigation of Relationship Between Spleen and Alzheimer' s Disease Based on Glucose, Lipid and Energy Metabolisms

Clinical Efficacy of Wumeiwan Combined with Bazhentang in Treatment of Obese of Type 2 Diabetes Mellitus Patients with Qi and Yin Deficiencies, Phlegm and Stasis

Effect of Compound Danshen Droppills on Vascular Endothelial Function in Early Diabetic Retinopathy Patients

Shugan Jianpi Decoction Treatment Early-stage Diabetes with 46 Cases

Related Author

JIN Tong

SHEN Yue

XU Zhaohui

WANG Haiying

Qin ZHENG

Jun LUO

De-lin ZHANG

Yu TANG

Related Institution

Shanghai University of Traditional Chinese Medicine（TCM）

Innovation Research Institute of TCM， Shanghai University of TCM

State Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Key Laboratory of Modern Chinese Medicine Preparations, Ministry of Education, Jiangxi University of Traditional Chinese Medicine

Guangxi University of Chinese Medicine

The First Affiliated Hospital of Guangxi University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰